The "Growth at a Reasonable Price" (GARP) strategy sits at an interesting intersection in investing: it looks for companies with strong earnings momentum that haven't yet been bid up to nosebleed valuations. It’s a middle-ground approach that avoids the raw speculation of pure growth plays while steering clear of the potential value traps that can plague deep-value hunting. To identify such candidates, we can use a structured fundamental screen that filters for stocks with strong growth scores, decent profitability and financial health, crucially combined with a valuation rating that suggests the market isn't overpaying for that expansion. One stock that has emerged from this screen is Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA), a commercial-stage biopharmaceutical company.
The Core Thesis: Growth and Valuation Hand-in-Hand
For a GARP stock, the most important balance is between how fast a company is growing and what you have to pay for that growth. The fundamental report for Kiniksa reveals a narrative that fits this mold exceptionally well. Let's start with the growth side, which earns a strong ChartMill Growth rating of 8 out of 10. This is not a story of hope and promise; the numbers show real, tangible momentum:
- Revenue Growth: The company's revenue has grown by an impressive 56.71% over the past year. Looking at a longer time horizon, the average annual revenue growth comes in at a solid 45.45% .
- Earnings Per Share (EPS) Growth: The bottom line is also improving dramatically, with EPS growing by 460% in the last year. This suggests the company is scaling effectively.
- Future Expectations: Analysts expect this momentum to continue. The EPS is projected to grow at an average rate of 44.85% per year over the next few years, with revenue forecast to increase by approximately 18.48% annually.
This type of growth often commands a high price premium. However, here is where the GARP criteria make a difference. Despite this impressive expansion, Kiniksa’s Valuation rating sits at 6 out of 10. While that is not a screaming bargain, it is above the screen's threshold of 5, indicating the stock is not yet overvalued relative to its industry. A look at the metrics shows why this is the case:
- Relative Valuation: The Price/Earnings (P/E) ratio of 66.10 is high in absolute terms, but it is actually cheaper than 91.23% of its peers in the Biotechnology industry. This suggests the sector as a whole is priced even more aggressively.
- PEG Ratio: The compensation for growth looks particularly favorable. A low PEG ratio, which divides the P/E by the earnings growth rate, indicates that the investor is not paying a full price for the future expansion.
- Cash Flow Multiple: The Price/Free Cash Flow ratio also ranks the stock as cheap compared to 92.59% of other companies in the same industry.
For the GARP investor, this combination is a key signal: the market is pricing the stock at a discount to its peer group despite the company delivering superior top- and bottom-line growth.
Quality Checks: Profitability and Financial Health
Growth at any price is a dangerous game, which is why this screen also requires decent scores for profitability and health. It is one thing to grow revenue; it is another to do so profitably and without taking on crippling debt.
Kiniksa earns a Profitability rating of 7 out of 10 and a Health rating of 7 out of 10.
The profitability profile shows a company that has crossed a major milestone:
- Operating Margin: At 12.36% , the operating margin is better than 92.79% of industry peers.
- Return on Equity (ROE): A ROE of 12.06% is also a top-tier result for the sector, outperforming 92.79% of competitors.
- Gross Margin: The gross margin stands at a very high 89.31% , which is typical for high-margin biotech products.
On the health side, the company presents a very clean balance sheet:
- Zero Debt: Kiniksa has no outstanding debt, making its Debt/Equity and Debt/FCF ratios a perfect zero. This is a massive safety buffer.
- Strong Liquidity: The current ratio of 3.79 and the quick ratio of 3.33 indicate the company has ample cash to cover its short-term obligations.
- Altman Z-Score: The Altman Z-Score of 13.68 is a strong indicator of financial stability, suggesting the risk of bankruptcy is currently very low.
This financial health is crucial for a growth-oriented investor. It means the current expansion is self-sustaining and not dependent on expensive external financing.
Putting It All Together
The fundamental report suggests that Kiniksa Pharmaceuticals presents a classic example of a GARP opportunity. It is delivering high revenue and earnings growth, operates with strong profit margins, and holds a debt-free balance sheet. Crucially, its valuation, while not cheap by absolute S&P 500 standards, is very reasonable compared to its high-growth industry peers. Investors looking for a company that is already profitable and growing with the potential for further upside can review the full fundamental analysis report for KNSA here.
Find More Affordable Growth Opportunities
Kiniksa is just one example of a stock passing this rigorous screen. The Affordable Growth methodology is designed to uncover a range of opportunities where solid fundamentals meet attractive pricing. To explore a broader list of stocks that meet these same criteria—good growth, decent profitability and health, and reasonable valuation—you can run the screen yourself.
Click here to view the full list of stocks from the Affordable Growth Stock Screen
Disclaimer: This article is for informational and educational purposes only. It does not constitute investment advice. You should consult a qualified financial professional before making any investment decisions.
Read full article here »
View the Zacks #1 Rank List
Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA) Presents a Compelling GARP Opportunity
The "Growth at a Reasonable Price" (GARP) strategy sits at an interesting intersection in investing: it looks for companies with strong earnings momentum that haven't yet been bid up to nosebleed valuations. It’s a middle-ground approach that avoids the raw speculation of pure growth plays while steering clear of the potential value traps that can plague deep-value hunting. To identify such candidates, we can use a structured fundamental screen that filters for stocks with strong growth scores, decent profitability and financial health, crucially combined with a valuation rating that suggests the market isn't overpaying for that expansion. One stock that has emerged from this screen is Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA), a commercial-stage biopharmaceutical company.
The Core Thesis: Growth and Valuation Hand-in-Hand
For a GARP stock, the most important balance is between how fast a company is growing and what you have to pay for that growth. The fundamental report for Kiniksa reveals a narrative that fits this mold exceptionally well. Let's start with the growth side, which earns a strong ChartMill Growth rating of 8 out of 10. This is not a story of hope and promise; the numbers show real, tangible momentum:
This type of growth often commands a high price premium. However, here is where the GARP criteria make a difference. Despite this impressive expansion, Kiniksa’s Valuation rating sits at 6 out of 10. While that is not a screaming bargain, it is above the screen's threshold of 5, indicating the stock is not yet overvalued relative to its industry. A look at the metrics shows why this is the case:
For the GARP investor, this combination is a key signal: the market is pricing the stock at a discount to its peer group despite the company delivering superior top- and bottom-line growth.
Quality Checks: Profitability and Financial Health
Growth at any price is a dangerous game, which is why this screen also requires decent scores for profitability and health. It is one thing to grow revenue; it is another to do so profitably and without taking on crippling debt.
Kiniksa earns a Profitability rating of 7 out of 10 and a Health rating of 7 out of 10.
The profitability profile shows a company that has crossed a major milestone:
On the health side, the company presents a very clean balance sheet:
This financial health is crucial for a growth-oriented investor. It means the current expansion is self-sustaining and not dependent on expensive external financing.
Putting It All Together
The fundamental report suggests that Kiniksa Pharmaceuticals presents a classic example of a GARP opportunity. It is delivering high revenue and earnings growth, operates with strong profit margins, and holds a debt-free balance sheet. Crucially, its valuation, while not cheap by absolute S&P 500 standards, is very reasonable compared to its high-growth industry peers. Investors looking for a company that is already profitable and growing with the potential for further upside can review the full fundamental analysis report for KNSA here.
Find More Affordable Growth Opportunities
Kiniksa is just one example of a stock passing this rigorous screen. The Affordable Growth methodology is designed to uncover a range of opportunities where solid fundamentals meet attractive pricing. To explore a broader list of stocks that meet these same criteria—good growth, decent profitability and health, and reasonable valuation—you can run the screen yourself.
Click here to view the full list of stocks from the Affordable Growth Stock Screen
Disclaimer: This article is for informational and educational purposes only. It does not constitute investment advice. You should consult a qualified financial professional before making any investment decisions.
Read full article here »